Pulmonx CorpLUNGEarnings & Financial Report
Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.
LUNG Q1 FY2026 Key Financial Metrics
Revenue
$20.6M
Gross Profit
$16.0M
Operating Profit
$-8.4M
Net Profit
$-13.7M
Gross Margin
77.9%
Operating Margin
-40.9%
Net Margin
-66.3%
YoY Growth
-8.7%
EPS
$-0.33
Pulmonx Corp Q1 FY2026 Financial Summary
Pulmonx Corp reported revenue of $20.6M (down 8.7% YoY) for Q1 FY2026, with a net profit of $-13.7M (up 5.5% YoY) (-66.3% margin). Cost of goods sold was $4.5M, operating expenses totaled $24.5M.
Key Financial Metrics
| Total Revenue | $20.6M |
|---|---|
| Net Profit | $-13.7M |
| Gross Margin | 77.9% |
| Operating Margin | -40.9% |
| Report Period | Q1 FY2026 |
Pulmonx Corp Annual Revenue by Year
Pulmonx Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $90.5M).
Pulmonx Corp Quarterly Revenue & Net Profit History
Pulmonx Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $20.6M | -8.7% | $-13.7M | -66.3% |
| Q4 FY2025 | $22.6M | -4.9% | $-10.4M | -46.1% |
| Q3 FY2025 | $21.5M | +5.5% | $-14.0M | -64.9% |
| Q2 FY2025 | $23.9M | +14.8% | $-15.2M | -63.6% |
| Q1 FY2025 | $22.5M | +19.5% | $-14.4M | -64.1% |
| Q4 FY2024 | $23.8M | +23.3% | $-13.2M | -55.4% |
| Q3 FY2024 | $20.4M | +15.4% | $-14.1M | -69.4% |
| Q2 FY2024 | $20.8M | +20.9% | $-15.3M | -73.7% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.8M | $20.4M | $23.8M | $22.5M | $23.9M | $21.5M | $22.6M | $20.6M |
| YoY Growth | 20.9% | 15.4% | 23.3% | 19.5% | 14.8% | 5.5% | -4.9% | -8.7% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $172.6M | $167.4M | $162.8M | $150.7M | $147.2M | $138.3M | $129.3M | $120.0M |
| Liabilities | $71.4M | $73.5M | $77.0M | $73.1M | $78.1M | $78.2M | $75.2M | $74.2M |
| Equity | $101.2M | $93.9M | $85.8M | $77.7M | $69.1M | $60.0M | $54.1M | $45.8M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-5.8M | $-7.2M | $-6.7M | $-13.2M | $-3.9M | $-8.2M | $-7.1M |